HEAL Initiative: Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain - (U44 Clinical Trial Not Allowed) | RFA NS 19 020

Opportunity Information: Apply for RFA NS 19 020

The funding opportunity titled "HEAL Initiative: Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain (U44 Clinical Trial Not Allowed)" is an NIH cooperative agreement aimed at moving promising, non-opioid pain treatment candidates through key preclinical steps so they are ready to enter human testing later. The core intent is to close the gap between early discovery and a credible, regulator-ready development package by supporting the kind of practical optimization and IND-enabling work that is often too expensive or operationally complex for small companies to do without targeted support. Although the long-term vision is to expand the pipeline of non-addictive pain therapeutics that can reach patients, this specific FOA is focused on preclinical optimization and development rather than clinical testing, and it explicitly does not allow clinical trials under this award.

Scientifically, the FOA targets two broad therapeutic modalities: small molecules and biologics. It is designed for projects that already have something real in hand, meaning a promising "hit" or "lead" candidate rather than a purely conceptual idea. Applicants are expected to present a strong biological rationale showing why their target, mechanism, or therapeutic approach should meaningfully affect pain pathways, and they must also have identified assays that can be used to optimize the agent. In practice, that means NIH is looking for teams that can measure and improve relevant properties of the candidate in a disciplined way, such as potency and selectivity in biochemical or cellular assays, functional activity tied to pain-relevant biology, and early indicators of developability like stability, solubility, or manufacturability depending on the modality.

The supported work spans a typical preclinical development arc. On the front end, the FOA covers optimization and early development activities, which commonly include medicinal chemistry or protein engineering iterations, structure-activity relationship work, in vitro profiling, formulation exploration, and early pharmacokinetics and pharmacodynamics planning. As the project matures, the scope extends into IND-enabling studies, the body of nonclinical testing generally needed to justify first-in-human studies. While the FOA text in your excerpt does not list every study type, IND-enabling packages typically involve more formal safety and toxicology work, dose range-finding, safety pharmacology considerations, and other elements expected by FDA for an IND submission, alongside a plan for manufacturing and quality appropriate for a clinical-grade material. The endpoint NIH is pushing applicants toward is not a clinical trial in this program, but rather a well-supported Investigational New Drug application assembly that positions the candidate to enter clinical evaluation under subsequent funding or investment.

From a program structure standpoint, this is a milestone-driven, phased cooperative agreement using the U44 mechanism. A cooperative agreement differs from a standard grant in that NIH program staff have substantial involvement in shaping and monitoring the project rather than simply providing funds and receiving periodic reports. Here, NIH staff participate in developing the project plan and then track progress against predefined milestones. This setup is meant to keep projects tightly aligned with translational go/no-go decision points, where advancement depends on meeting performance and development benchmarks. In practical terms, applicants need to propose clear, measurable milestones and a credible development plan with decision criteria, because continued progress and support are tied to achieving those milestones.

Eligibility is limited to small businesses, consistent with the U44 mechanism. The FOA also places clear restrictions on foreign participation at the applicant level: non-U.S. (non-domestic) entities and non-U.S. components of U.S. organizations are not eligible to apply. However, it leaves room for "foreign components" as defined by NIH policy to be allowed in some cases, which usually means certain discrete project elements could be conducted outside the U.S. with appropriate justification and compliance, even though the applicant organization itself must be domestic and the project cannot be primarily foreign. This distinction matters for companies that rely on specialized overseas testing or manufacturing capabilities, since it signals that limited foreign subcontracting or collaboration may be possible if it meets NIH policy requirements.

Administratively, the opportunity is run by the National Institutes of Health and was published as RFA-NS-19-020 under a discretionary funding category. It is associated with multiple CFDA numbers (93.121, 93.213, 93.273, 93.279, 93.313, 93.350, 93.393, 93.847, 93.853, 93.865), reflecting the NIH-wide nature of HEAL-related and pain-related research funding streams. The original closing date listed for this specific announcement was June 4, 2019, and the creation date was December 10, 2018. The excerpt you provided does not specify an award ceiling or the expected number of awards, but the program’s design suggests NIH intended to support a portfolio of projects and advance only those that hit the required milestones.

Overall, the FOA is best understood as a translational "bridge" for small businesses that have a credible non-addictive pain therapeutic lead and need structured support to optimize the candidate, generate the development data expected by regulators, and assemble an IND-ready package. The emphasis is on tangible progress toward clinical readiness while keeping the work firmly in the preclinical lane, with NIH staff actively engaged to keep timelines, study design, and milestone decisions focused on what will realistically enable a first-in-human entry later on.

• The National Institutes of Health in the education, food and nutrition, health, income security and social services sector is offering a public funding opportunity titled "HEAL Initiative: Optimization of Non-addictive Therapies [Small Molecules and Biologics] to Treat Pain - (U44 Clinical Trial Not Allowed)" and is now available to receive applicants.
• Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121, 93.213, 93.273, 93.279, 93.313, 93.350, 93.393, 93.847, 93.853, 93.865.
• This funding opportunity was created on 2018-12-10.
• Applicants must submit their applications by 2019-06-04. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
• Eligible applicants include: Small businesses.

Apply for RFA NS 19 020

[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal: